<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00399477</url>
  </required_header>
  <id_info>
    <org_study_id>TVP-1012/PM101</org_study_id>
    <nct_id>NCT00399477</nct_id>
  </id_info>
  <brief_title>A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease</brief_title>
  <official_title>Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Neuroscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at
      their first visit based on the drugs they are taking for their PD:

        -  Group 1 Patients using Azilect and no other therapy.

        -  Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To identify the earliest scheduled visit of symptomatic effect</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the effectiveness of Azilect in a usual community neurological</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Rasagiline mesylate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rasagiline mesylate plus adjunct therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rasagiline mesylate with one of three adjunct therapies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rasagiline mesylate</intervention_name>
    <description>Azilect®</description>
    <arm_group_label>Rasagiline mesylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline mesylate plus Mirapex</intervention_name>
    <description>Mirapex, Azilect®</description>
    <arm_group_label>Rasagiline mesylate plus adjunct therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline mesylate with Levodopa</intervention_name>
    <description>Azilect®, Levodopa</description>
    <arm_group_label>Rasagiline mesylate plus adjunct therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline mesylate with Requip</intervention_name>
    <description>Azilect®, Requip</description>
    <arm_group_label>Rasagiline mesylate plus adjunct therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Idiopathic Parkinson's disease. Diagnosis previously confirmed by the presence of
             bradykinesia and by at least one additional cardinal sign (i.e., resting tremor,
             rigidity), without other known or suspected cause of parkinsonism.

          2. Requiring therapy for PD symptom control

               -  Azilect monotherapy.

               -  Azilect as adjunct therapy..

        Exclusion Criteria:

          1. Patients previously exposed to Azilect

          2. Patients with pheochromocytoma

          3. Concomitant MAO inhibitors or medications contraindicated for use with MAO inhibitors
             are not allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MerriKay Oleen-Burkey, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Neuroscience, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2006</study_first_submitted>
  <study_first_submitted_qc>November 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <last_update_submitted>April 8, 2011</last_update_submitted>
  <last_update_submitted_qc>April 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thomas Smith, MD</name_title>
    <organization>Teva Neuroscience</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Ropinirole</mesh_term>
    <mesh_term>Pramipexole</mesh_term>
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

